Archives: 2024-01-24

PIER MARIA FORNASARI
2024-01-24

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF)

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2024-01-20

New research finds half-cardio, half-strength training reduces cardiovascular disease risks

Approximately one in three deaths in the U.S. is caused by cardiovascular disease, according to the U.S. Centers for Disease Control and Prevention. A robust body of evidence shows aerobic exercise can reduce risks, especially for people who are overweight or obese. But few studies have compared results with resistance exercise — also known as strength

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2024-01-20

The cause of Guillain-Barré syndrome elucidated

Guillain-Barré syndrome is a rare disease in which the immune system attacks the peripheral nerves. Those affected suffer from muscle weakness and paralysis. A research team led by ETH Zurich has now elucidated the mechanism of this autoimmune reaction. Patients with Guillain-Barré syndrome (GBS) suffer from a rare and diverse disorder of the peripheral nervous

Read More

No Comments InAUTOIMMUNE DISEASES Uncategorized